About the Company
Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $REXN News
Buy Rating Affirmed for Ocuphire Pharma on Promising APX3330 Progress for Diabetic Retinopathy Treatment
H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on Ocuphire Pharma (OCUP – Research Report) today and set a price target ...
Lexicon stock rallies 18% amid FDA update, $250M private placement
Lexicon (LXRX) stock rallied 18% amid a regulatory update for its diabetes drug candidate sotagliflozin and the announcement ...
Amring Pharmaceuticals Rebrands as Nordic Pharma, Eyes Global Expansion with Strategic Acquisition
BERWYN, PA — Amring Pharmaceuticals Inc. has announced a corporate name change to Nordic Pharma, Inc., marking a new chapter ...
Marinus Pharmaceuticals: Q4 Earnings Snapshot
(MRNS) on Tuesday reported a loss of $41.8 million in its fourth quarter. The Radnor, Pennsylvania-based company said it had a loss of 74 cents per share. The results did not meet Wall Street ...
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q4 2023 Earnings Call Transcript
Q4 2023 Earnings Call Transcript March 5, 2024 Marinus Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is ...
Loading the latest forecasts...